<DOC>
	<DOCNO>NCT00295633</DOCNO>
	<brief_summary>The purpose clinical research study learn whether Saxagliptin add thiazolidinedione ( TZD ) therapy effective TZD alone treatment Type 2 diabetic subject sufficiently control TZD alone</brief_summary>
	<brief_title>A Study Assessing Saxagliptin Treatment Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone</brief_title>
	<detailed_description>All subject participate lead-in period , qualify subject continue short-term randomized treatment period . Subjects complete short-term period eligible enter long term extension period . Also , subject short-term period elevate blood sugar require additional medication blood sugar control eligible enter long-term treatment extension period receive metformin ( define rescue medication ) add onto blind study medication</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 diabetic currently receive stable dose TZD monotherapy ( pioglitazone 30mg 45mg , rosiglitazone 4mg 8mg ) least 12 week prior screen . Hemoglobin A1c ( HbA1c ) &gt; = 7.0 % &lt; = 10.5 % Body mass index &lt; = 45kg/m2 Fasting Cpeptide &gt; = 1 ng/mL Symptomatic poorly control diabetes Recent cardiac cerebrovascular event Serum creatinine &gt; = 2.0 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>77 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>